General Information
Novo Nordisk NN9535-4216
Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes
| Protocol | NN9535-4216 |
|---|---|
| Identifier | Site No: 846 V#1157252 |
| UID | c343e969-ac71-43ce-b537-4c64985fa1bb |
| Status | Done - Archived |
| Phase | 3b |
| Category | Diabetes Type 2 |
| Launch Year | 2016 |
| NCT Number | - |
| Created | 2015-09-18 13:37 |
| Last Updated | 2015-09-18 13:37 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2016-02-06 | No |
| Enrollment Open | 2016-01-06 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2015-12-09 | No |
| PI Meeting Start | 2015-09-28 | No |
| PI Meeting End | 2015-09-29 | No |
| PI Meeting Arrival | 2015-09-28 | No |
| PI Meeting Departure | 2015-09-29 | No |
| Closeout Date | 2017-08-10 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | - | No | |
| Coordinator | Soler, Daniel | DSoler | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Novo Nordisk |
|---|---|
| Division | Novo Nordisk |
| Team | Novo Nordisk |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
